Cytiva Announces Layoffs at Massachusetts Facility Amid Ongoing Industry Restructuring

In a sign of continued pressure on the biopharmaceutical sector, life sciences technology and service provider Cytiva has announced a significant round of layoffs at its Westborough, Massachusetts facility. The move comes as part of a broader trend of workforce reductions across the pharmaceutical industry in 2025.

Cytiva Cuts 85 Jobs in Westborough

Cytiva, a subsidiary of Danaher Corporation, will lay off 85 employees from its Westborough, Massachusetts site, according to a Worker Adjustment and Retraining Notification (WARN) alert filed with the state. The layoffs are set to begin on March 7 and will continue throughout the month, with any remaining affected employees being let go at a later date.

A Cytiva spokesperson confirmed the cuts, stating that they were part of the company's "regular business mechanism" involving continuous review to ensure long-term success and competitiveness. The spokesperson emphasized that these actions were part of longer-term business planning to maintain the health and competitiveness of the business.

While specific details about the affected roles were not disclosed, job listings for the Westborough facility suggest it focuses on manufacturing, particularly in areas such as single-use technologies. The site appears to house positions including manufacturing engineers, processing scientists, and downstream process development managers.

Industry-Wide Restructuring Continues

Cytiva's announcement is part of a larger trend of job cuts across the biopharmaceutical industry. In recent days, several prominent companies have unveiled plans for workforce reductions:

• Bristol Myers Squibb has announced the elimination of 223 jobs in New Jersey as part of its ongoing cost-savings initiatives.
• CRISPR Therapeutics has implemented staff cuts, though specific numbers were not provided.
• Eisai is parting ways with 121 employees in a new US restructuring effort.

Smaller biotechnology firms have not been immune to the trend, with companies such as Ryvu Therapeutics, Lava Therapeutics, and Repare Therapeutics also trimming their headcounts in recent days.

These layoffs follow several years of steady job cuts in the industry, indicating that the sector's restructuring efforts are far from over as companies continue to seek ways to streamline operations and reduce costs in a challenging economic environment.